Privacyvoorkeur
MEDtalks houdt u graag op de hoogte van de laatste ontwikkelingen op uw interessegebied. Kies hieronder of u op de hoogte gehouden wilt blijven van de nieuwste programma's en nascholingen binnen uw interessegebieden. Klik hier voor meer informatie.
Oncologiejournaal 2022 | Mammacarcinoom
37 min.
Dr. Marleen Kok en dr. Inge Konings bespreken het belangrijkste ASCO-nieuws op het gebied van mammacarcinoom door.
De volgende onderwerpen staan op het programma:
Oligometastasen
Update antibody drug conjugates
- Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
- Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
- Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
- Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
- Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
CDK4/6-remming
- Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
- A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
Vroeg stadium triple negatief mammacarcinoom
- Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
- Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).
Bekijk hier het volledige overzicht van onze ASCO 2022 oncologiejournaals en interviews.
Laatst bewerkt: 19-12-2023
-
Sponsoren
De Oncologiejournaals en interviews rond ASCO 2022 komen onafhankelijk tot stand en worden financieel mogelijk gemaakt door hoofdsponsor BMS en sponsoren AstraZeneca | Daiichi Sankyo, Ipsen, Pfizer, Roche. -
-
-
-
Specialisme
-
Tags